No. 12: Becton, Dickinson
Franklin Lakes, N.J.
www.bd.com
2016 RANK: 8
Revenue: $8,654,000,000*
Fiscal year ending: Sept. 30, 2016
Employees: 24,000
Key Personnel:
Vincent Forlenza, chairman & CEO; Thomas Polen, president; Gary Cohen EVP & president, global health; Alexandre Conroy, EVP & president, Europe, EMA & Americas; James Lim, EVP & president, greater Asia; Alberto Mas, EVP & president, life sciences; Christopher Reidy, EVP, CFO & chief administrative officer; Nabil Shabshab, EVP, strategic planning & chief marketing officer; Jeffrey Sherman, EVP & general counsel; Stephen Sichak, EVP, integrated supply chain; Ellen Strahlman, EVP, R&D & CMO; Linda Tharby, EVP & chief HR officer; Pierre Boisier, EVP & chief quality officer; Linda Peters, EVP & chief regulatory officer; Richard Pierle, EVP & CIO
Description:
Becton, Dickinson through its BD Medical business segment produces a wide array of medical technologies for health providers. BD Medical has four major business units:
- Diabetes Care makes syringes, pen needles and IV sets;
- Medication and Procedural Solutions offers needles, syringes and intravenous catheters for medication delivery – and much more;
- Medication Management Solutions makes intravenous medication safety and infusion therapy delivery systems;
- Pharmaceutical Systems creates refillable drug delivery systems for pharmaceutical companies.
Plans for a $24 billion merger with C. R. Bard, expected to close this year, should make BD even more of a major presence in the medical device industry.
* Revenues from Becton, Dickinson’s medical segment.
And you can also pick up a free hard copy of the Big 100 issue at DeviceTalks Boston on Oct. 2!
Chris Newmarker says
Apologies. We had to fix a technical glitch with the Big 100 spreadsheet download. If you fill out the sign-up form now, you should get an email with a link to download the spreadsheet, instead of last year’s Big 100 edition.
Mark Russell Filaroski says
Chris, Thank you for the update. I just downloaded the Big 100.
Chris Newmarker says
Glad this helped, Mark.